UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) 47-5586242 Delaware (State of incorporation or organization) (I.R.S. Employer Identification No.) 100 Campus Drive, 6th Floor, Marlborough, MA 01752 (Address of principal executive offices) (Zip Code) Securities to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which to be so registered each class is to be registered Common Stock, \$0.00001 par value per share The Nasdaq Stock Market LLC If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. \boxtimes If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. \Box If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. \Box Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-254760

Securities to be registered pursuant to Section 12(g) of the Act: None.

Item 1. Description of Registrant's Securities to be Registered.

The description of the Common Stock, par value \$0.00001 per share, of Akoya Biosciences, Inc. (the "Registrant") under the heading "Description of Capital Stock" in the prospectus included in the Registrant's Registration Statement on Form S-1 (File No. 333-254760), as initially filed with the Securities and Exchange Commission on March 26, 2021, including exhibits, and as may be subsequently amended (the "Registration Statement"), is hereby incorporated by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.

Item 2. Exhibits.

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market, LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 15, 2021

Akoya Biosciences, Inc.

By: /s/ Brian McKelligon
Brian McKelligon

Chief Executive Officer